Krystal Biotech (KRYS) Expected to Announce Quarterly Earnings on Wednesday

Krystal Biotech (NASDAQ:KRYS) is expected to be posting its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect Krystal Biotech to post earnings of $1.62 per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 8:30 AM ET.

Krystal Biotech Trading Down 0.7%

Krystal Biotech stock opened at $270.70 on Wednesday. Krystal Biotech has a 1-year low of $122.80 and a 1-year high of $295.98. The firm’s fifty day simple moving average is $259.14 and its 200-day simple moving average is $203.54. The company has a market capitalization of $7.85 billion, a P/E ratio of 40.58 and a beta of 0.49.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on KRYS shares. Zacks Research lowered Krystal Biotech from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Chardan Capital increased their price objective on Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Bank of America boosted their target price on Krystal Biotech from $288.00 to $318.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. Citigroup increased their price target on Krystal Biotech from $320.00 to $336.00 and gave the company a “buy” rating in a report on Monday, January 12th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Krystal Biotech in a research report on Monday, December 29th. Nine investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $277.89.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $220.16, for a total value of $5,504,000.00. Following the sale, the insider owned 1,413,711 shares of the company’s stock, valued at $311,242,613.76. The trade was a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 13.70% of the company’s stock.

Institutional Trading of Krystal Biotech

Several institutional investors have recently bought and sold shares of KRYS. State Street Corp lifted its holdings in shares of Krystal Biotech by 10.5% during the second quarter. State Street Corp now owns 1,355,346 shares of the company’s stock valued at $186,306,000 after acquiring an additional 128,639 shares during the period. Soleus Capital Management L.P. grew its stake in shares of Krystal Biotech by 108.9% during the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after purchasing an additional 481,200 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Krystal Biotech by 5.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 533,964 shares of the company’s stock valued at $94,261,000 after buying an additional 28,075 shares during the period. Millennium Management LLC increased its position in Krystal Biotech by 1,083.8% in the third quarter. Millennium Management LLC now owns 148,713 shares of the company’s stock worth $26,252,000 after purchasing an additional 136,151 shares during the period. Finally, Bank of America Corp DE grew its position in shares of Krystal Biotech by 13.3% during the 3rd quarter. Bank of America Corp DE now owns 137,995 shares of the company’s stock worth $24,360,000 after buying an additional 16,183 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.